Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
50 Leser
Artikel bewerten:
(0)

Manuela Leone MD Joins Aptuit Leadership Team As Executive V.P. And Verona General Manager

GREENWICH, Connecticut, Oct. 9, 2014 /PRNewswire/ -- Aptuit LLC announced the appointment of Dr. Manuela Leone as Executive Vice President, Operations and General Manager of the Aptuit Center for Drug Discovery & Development in Verona, Italy. In this role, Dr. Leone will be overseeing Aptuit's drug discovery and development operations.

Dr. Leone has been in global R&D executive management, general management and presidential roles for the past 20 years. Most recently, she was with Harlan Laboratories, where she was President of Contract Research Services where she helped create a globalized integrated organization. Prior to this, Dr. Leone was with ICON Clinical Research where she served as Senior Vice President of Clinical Operations and Strategic Alliances. Before joining ICON, Dr. Leone was a Global Head of Clinical Development and Development Operations with Galderma Pharmaceuticals following leadership positions at Fidia S.p.A. and Pharmacia, Upjohn in Milan.

Dr. Leone earned a Summa Cum Laude Doctor of Medicine (MD) degree from the University of Pavia in 1985, followed by post-graduate training in pediatrics and immunology at Necker Hospital, the University of Paris. She practiced pediatric medicine until 1995.

Dr. Jonathan Goldman, Aptuit's CEO, stated, "I am delighted to welcome Dr. Leone to our company. She brings real depth and breadth of executive management experience in Pharma and CRO. Dr. Leone's appointment further enhances Aptuit's status as the leading global provider of fully integrated discovery and integrated expertise, and the only CRO to provide these solutions under one roof at a former large pharma R&D center."

For more information, please send an email to info@aptuit.com or contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com.

Join us on October 15th at the British Consulate in Boston for this important seminar: Partnership for Therapeutic Success: Innovation in Early Drug Development. You can register or get more information here: http://innovation-early-drug-development.eventbrite.com

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Pharmaceutical Sciences and Aptuit INDiGO® (a fixed-cost program that accelerates drug development). Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 700 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.